Just four days ago in the world of Valeant, no one had ever heard of Philidor RX. Recent concerns about the company focused on its unsavory business practices of massive price raises on pharmaceuticals acquired in a rapid succession of acquisitions, while slashing research and development. But no one had discussed how these drugs were distributed….until this week.
Now Valeant has made new disclosures regarding its distribution channel, and they’ve led the company into a web of deception that … you have to read for yourselves.
/wp-content/uploads/2017/05/CitronLogo2017-350x65-1.png00Citron Research/wp-content/uploads/2017/05/CitronLogo2017-350x65-1.pngCitron Research2015-10-21 06:06:532017-05-29 05:06:40Valeant -- Could this be the Pharmaceutical Enron ?